TG THERAPEUTICS INC (TGTX)

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I...

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the...

TG Therapeutics Becomes Oversold (TGTX)

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II...

TG Therapeutics Breaks Below 200-Day Moving Average - Notable for TGTX

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II...

Notable Wednesday Option Activity: TGTX, TMCI, NVTS

TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?

The company reported in-line sales for the fourth quarter, but shares soared by double digits.

TG Therapeutics stock jumps after Q4 beat (NASDAQ:TGTX)

TG Therapeutics (TGTX) stock soars on better-than-expected Q4 2023 financials. Read more here.

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today,...

TG Therapeutics Q4 2023 Earnings Preview (NASDAQ:TGTX)

TG Therapeutics is set to announce Q4 earnings results on February 28th.

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

Newly issued patents extend exclusivity of ublituximab through 2042...

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...

7 Exciting Stocks Poised for Explosive Growth in Key Sectors

These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns.

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

TG Therapeutics Adds To Its 225% Sprint After MS Drug Crushes Sales Estimates

The company makes a treatment for relapsing forms of multiple sclerosis.

TG Therapeutics prelim results sees FY23 BRIUMVI U.S. revenue $89M; initiates FY24 outlook

Ahead of the the ongoing annual J.P. Morgan Healthcare Conference, shares of Therapeutics (TGTX) jumped more than 10% in early trading on Wednesday after the biopharmaceutical company issu